查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1957730

2026年全球放射性藥物市場報告

Radiopharmaceuticals Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，放射性藥物市場發展迅速。預計該市場將從2025年的73億美元成長到2026年的82.5億美元，複合年成長率（CAGR）為13.0%。過去幾年的成長歸因於核醫學影像技術的普及、癌症診斷率的提高、放射性同位素的供應、醫院核子醫學科室的擴建以及診斷試劑的監管核准等因素。

預計未來幾年放射性藥物市場將快速成長，到2030年將達到136.8億美元，複合年成長率（CAGR）為13.5%。預測期內的成長要素包括精準腫瘤學的進步、標靶放射線治療需求的成長、診斷影像中心的擴張、迴旋加速器設施的投資以及同位素生產技術的進步。預測期內的主要趨勢包括放射性藥物在腫瘤學中的應用日益廣泛、治療診斷學（治療性診斷）應用的成長、PET和SPECT成像技術的擴展、靶向放射治療技術的快速發展以及核醫學基礎設施的改善。

隨著癌症和心血管疾病發生率的不斷上升，對放射性藥物的需求預計將會成長。與傳統藥物相比，放射性藥物正逐漸被公認為更安全、更有效的治療選擇。其標靶治療和精準治療等優勢，使放射科醫師在治療癌症和心血管疾病方面擁有顯著優勢。癌症是全球第二大死因，約佔全球死亡總數的六分之一。例如，根據總部位於法國的國際癌症研究機構（IARC）的數據，2022年全球報告了約2,000萬例新增癌症病例和970萬例癌症相關死亡病例。預計到2040年，這些數字將分別增加至每年2,990萬例新增病例和1,530萬例死亡病例。因此，癌症和心血管疾病發生率的上升預計將顯著推動用於治療這些疾病的放射性藥物的需求。

放射性藥物市場的主要企業正在加強策略合作，以加速創新並擴大先進診斷和治療解決方案的可及性。這些合作旨在促進放射性藥物的研發，提升區域生產能力，並滿足日益成長的精準成像和標靶治療需求。例如，2023年6月，總部位於美國的匹茲堡大學醫學中心（UPMC）與PharmaLogic控股公司合作，在其匹茲堡工廠啟動一種新型放射性藥物的聯合研發和生產。此次合作旨在使周邊地區難以獲得的先進診斷和治療藥物能夠更廣泛地惠及患者和醫療專業人員。根據一項非專屬協議，UPMC和PharmaLogic將促進實驗性放射性藥物轉化為臨床適用產品，從而支持創新核醫學療法的廣泛商業化和快速部署。

目錄

第1章執行摘要

第2章 市場特徵

  • 市場定義和範圍
  • 市場區隔
  • 主要產品和服務概述
  • 全球放射性藥物市場：吸引力評分及分析
  • 成長潛力分析、競爭評估、策略適宜性評估、風險狀況評估

第3章 市場供應鏈分析

  • 供應鏈與生態系概述
  • 清單：主要原料、資源和供應商
  • 主要經銷商和通路合作夥伴名單
  • 主要最終用戶列表

第4章：全球市場趨勢與策略

  • 關鍵科技與未來趨勢
    • 生物技術、基因組學和精準醫療
    • 人工智慧（AI）和自主人工智慧
    • 數位化、雲端運算、巨量資料、網路安全
    • 工業4.0和智慧製造
    • 永續性、氣候技術、循環經濟
  • 主要趨勢
    • 擴大放射性藥物在腫瘤學領域的應用
    • 治療診斷學應用領域的成長
    • PET和SPECT影像技術的擴展
    • 標靶放射線治療的發展日益加快
    • 改善核醫基礎設施

第5章 終端用戶產業市場分析

  • 醫院及門診手術中心
  • 診斷影像中心
  • 癌症治療中心
  • 核子醫學診所
  • 研究機構

第6章 市場：宏觀經濟情景，包括利率、通貨膨脹、地緣政治、貿易戰和關稅的影響、關稅戰和貿易保護主義對供應鏈的影響，以及 COVID-19 疫情對市場的影響。

第7章：全球策略分析架構、目前市場規模、市場對比及成長率分析

  • 全球放射性藥物市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 全球放射性藥物市場規模、對比及成長率分析
  • 全球放射性藥物市場表現：規模與成長，2020-2025年
  • 全球放射性藥物市場預測：規模與成長，2025-2030年，2035年預測

第8章：全球市場總規模（TAM）

第9章 市場細分

  • 按類型
  • 用於診斷和治療目的
  • 透過使用
  • 腫瘤學、心臟病學、胃腸病學、神經內分泌學、肌肉骨骼系統、呼吸系統、腎臟病學及其他應用領域。
  • 最終用戶
  • 醫院及門診手術中心、診斷中心、癌症研究所
  • 按類型細分：診斷
  • 用於正子斷層掃描（PET）的放射性藥物，用於單光子發射電腦斷層掃描（SPECT）的放射性藥物
  • 按類型細分：治療
  • α粒子發射裝置、BETA粒子發射裝置、近距離治療

第10章 區域與國別分析

  • 全球放射性藥物市場：按地區分類，實際數據和預測數據，2020-2025年、2025-2030年、2035年
  • 全球放射性藥物市場：按國家/地區分類，實際數據和預測數據，2020-2025年、2025-2030年、2035年

第11章 亞太市場

第12章：中國市場

第13章：印度市場

第14章：日本市場

第15章：澳洲市場

第16章：印尼市場

第17章：韓國市場

第18章 台灣市場

第19章 東南亞市場

第20章 西歐市場

第21章英國市場

第22章：德國市場

第23章：法國市場

第24章：義大利市場

第25章：西班牙市場

第26章：東歐市場

第27章：俄羅斯市場

第28章 北美市場

第29章：美國市場

第30章：加拿大市場

第31章：南美市場

第32章：巴西市場

第33章 中東市場

第34章：非洲市場

第35章 市場監理與投資環境

第36章：競爭格局與公司概況

  • 放射性藥物市場：競爭格局及市場佔有率（2024年）
  • 放射性藥物市場：公司估值矩陣
  • 放射性藥物市場：公司概況
    • Cardinal Health
    • Curium Pharma
    • Siemens Healthineers AG
    • Novartis AG
    • General Electric Company（GE）

第37章 其他大型企業和創新企業

  • IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging SpA, Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation（CIRC）, Alliance Medical, Advanced Accelerator Applications, JSC Isotope

第38章：全球市場競爭基準分析與儀錶板

第39章 重大併購

第40章：高潛力市場國家、細分市場與策略

  • 2030年放射性藥物市場：提供新機會的國家
  • 2030年放射性藥物市場：充滿新機會的細分市場
  • 2030年放射性藥物市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手的策略

第41章附錄

簡介目錄
Product Code: PH6MRADI02_G26Q1

Radiopharmaceuticals are medications that contain radioactive substances and are used for the diagnosis or treatment of diseases, including cancer. Also known as radioactive drugs, they are employed to identify specific illnesses or detect medical conditions. These medications can be administered to patients through various methods, such as injection, oral intake, or delivery into areas like the eye or bladder.

The primary types of radiopharmaceuticals include diagnostic, therapeutic, and others. Radiopharmaceutical therapeutics involve the delivery of radioactive atoms to targets associated with tumors. These agents are used across applications such as oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and others, and are utilized by hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and other healthcare facilities.

Tariffs have influenced the radiopharmaceuticals market by increasing costs related to radioisotope imports, nuclear medicine equipment, and specialized transportation systems. Diagnostic and therapeutic radiopharmaceutical segments are particularly affected due to time-sensitive supply chains. North america and europe face operational challenges because of cross-border isotope dependency. However, tariffs are driving investments in domestic isotope production and regional cyclotron facilities. These efforts are improving supply reliability and supporting long-term market growth.

The radiopharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides radiopharmaceuticals market statistics, including radiopharmaceuticals industry global market size, regional shares, competitors with a radiopharmaceuticals market share, detailed radiopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceuticals industry. This radiopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The radiopharmaceuticals market size has grown rapidly in recent years. It will grow from $7.3 billion in 2025 to $8.25 billion in 2026 at a compound annual growth rate (CAGR) of 13.0%. The growth in the historic period can be attributed to adoption of nuclear imaging technologies, growth in cancer diagnosis rates, availability of radioisotopes, hospital-based nuclear medicine expansion, regulatory approvals for diagnostic agents.

The radiopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $13.68 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growth in precision oncology, rising demand for targeted radiotherapies, expansion of diagnostic imaging centers, investments in cyclotron infrastructure, technological advancements in isotope production. Major trends in the forecast period include rising use of radiopharmaceuticals in oncology, growth of theranostics applications, expansion of pet and spect imaging, increasing development of targeted radiotherapies, improved nuclear medicine infrastructure.

The growing prevalence of cancer and cardiovascular diseases is expected to increase demand for the radiopharmaceuticals market. Radiopharmaceuticals are gaining recognition as safe and effective therapeutic options compared with conventional medicines. They offer significant advantages to radiologists in the treatment of cancer and cardiovascular conditions due to benefits such as targeted therapy and precision treatment. Cancer is the second leading cause of death globally, accounting for approximately one in six deaths worldwide. For example, in April 2024, according to the International Agency for Research on Cancer (IARC), a France-based specialized agency, nearly 20 million new cancer cases and 9.7 million cancer-related deaths were reported worldwide in 2022. These figures are projected to rise to 29.9 million new cases and 15.3 million deaths annually by 2040. Consequently, the increasing incidence of cancer and cardiovascular diseases is expected to significantly boost demand for radiopharmaceuticals used in their treatment.

Major companies operating in the radiopharmaceuticals market are increasingly engaging in strategic partnerships to accelerate innovation and broaden access to advanced diagnostic and therapeutic solutions. These collaborations aim to strengthen radiopharmaceutical development, enhance regional manufacturing capabilities, and meet the rising demand for precision imaging and targeted therapies. For instance, in June 2023, the University of Pittsburgh Medical Center (UPMC), a US-based hospital system, partnered with PharmaLogic Holdings Corporation to jointly develop and manufacture new radiopharmaceuticals at a facility in Pittsburgh. This partnership is intended to expand access for patients and clinicians to advanced diagnostic and therapeutic agents that are not readily available in surrounding regions. Under the non-exclusive agreement, UPMC and PharmaLogic will convert experimental radiopharmaceuticals into clinically viable products, supporting broader commercialization and faster adoption of innovative nuclear medicine treatments.

In January 2024, Eli Lilly, a US-based pharmaceutical company, completed the acquisition of Point Biopharma for approximately $1.4 billion. This acquisition aligns with Lilly's strategy to strengthen its position in the growing field of radioligand therapies, which offer promising advancements in cancer treatment. Point Biopharma specializes in radiopharmaceutical development, complementing Lilly's oncology portfolio and supporting efforts to improve patient outcomes. Point Biopharma is a US-based company focused on developing targeted radioligand therapies for multiple cancer types.

Major companies operating in the radiopharmaceuticals market are Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, UJV Rez, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacybapy-Monrol Nuclear Products, NTP Radioisotopes.

North America was the largest region in the global radiopharmaceuticals market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the radiopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radiopharmaceuticals market consists of sales of technetium disofenin, technetium lidofenin, and technetium mebrofenin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radiopharmaceuticals Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses radiopharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radiopharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radiopharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type: Diagnostic; Therapeutic
  • 2) By Application: Oncology; Cardiology; Gastroenterology; Neuroendocrinology; Musculoskeletal; Respiratory; Nephrology; Other Applications
  • 3) By End User: Hospitals And Ambulatory Surgical Centers; Diagnostic Centers; Cancer Research Institutes
  • Subsegments:
  • 1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals; Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
  • 2) By Therapeutic: Alpha Emitters; Beta Emitters; Brachytherapy
  • Companies Mentioned: Cardinal Health; Curium Pharma; Siemens Healthineers AG; Novartis AG; General Electric Company (GE); IBA Group; Bayer AG; Lantheus Medical Imaging Inc.; Bracco Imaging S.p.A.; Eckert & Ziegler; Nihon Medi-Physics Co. Ltd.; Fujifilm Corporation; ANSTO; Yantai Dongcheng Pharmaceutical Group Co. Ltd.; Bracco Imaging SpA.; Canon Inc.; China Isotope & Radiation Corporation (CIRC); Alliance Medical; Advanced Accelerator Applications; JSC Isotope; Pharm-Sintez; Synektik SA; Polatom; RadioMedic sro; UJV Rez; Actinium Pharmaceuticals Inc.; Alseres Pharmaceuticals Inc.; Avid Radiopharmaceuticals; Fusion Pharmaceuticals; Peregrine Pharmaceuticals Inc.; PETNET Solutions Inc.; Positron Corporation; Triad Isotopes Inc.; Telix Pharmaceuticals; Rosatom; Alliance Medical Group; Hologic Inc.; Segami Corporation; Eczacybapy-Monrol Nuclear Products; NTP Radioisotopes.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Radiopharmaceuticals Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Radiopharmaceuticals Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Radiopharmaceuticals Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Radiopharmaceuticals Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Sustainability, Climate Tech & Circular Economy
  • 4.2. Major Trends
    • 4.2.1 Rising Use Of Radiopharmaceuticals In Oncology
    • 4.2.2 Growth Of Theranostics Applications
    • 4.2.3 Expansion Of PET And SPECT Imaging
    • 4.2.4 Increasing Development Of Targeted Radiotherapies
    • 4.2.5 Improved Nuclear Medicine Infrastructure

5. Radiopharmaceuticals Market Analysis Of End Use Industries

  • 5.1 Hospitals And Ambulatory Surgical Centers
  • 5.2 Diagnostic Imaging Centers
  • 5.3 Cancer Treatment Centers
  • 5.4 Nuclear Medicine Clinics
  • 5.5 Research Institutes

6. Radiopharmaceuticals Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Radiopharmaceuticals Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Radiopharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Radiopharmaceuticals Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Radiopharmaceuticals Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Radiopharmaceuticals Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Radiopharmaceuticals Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Radiopharmaceuticals Market Segmentation

  • 9.1. Global Radiopharmaceuticals Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Diagnostic, Therapeutic
  • 9.2. Global Radiopharmaceuticals Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications
  • 9.3. Global Radiopharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes
  • 9.4. Global Radiopharmaceuticals Market, Sub-Segmentation Of Diagnostic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Positron Emission Tomography (PET) Radiopharmaceuticals, Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
  • 9.5. Global Radiopharmaceuticals Market, Sub-Segmentation Of Therapeutic, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Alpha Emitters, Beta Emitters, Brachytherapy

10. Radiopharmaceuticals Market Regional And Country Analysis

  • 10.1. Global Radiopharmaceuticals Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Radiopharmaceuticals Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Radiopharmaceuticals Market

  • 11.1. Asia-Pacific Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Radiopharmaceuticals Market

  • 12.1. China Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Radiopharmaceuticals Market

  • 13.1. India Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Radiopharmaceuticals Market

  • 14.1. Japan Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Radiopharmaceuticals Market

  • 15.1. Australia Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Radiopharmaceuticals Market

  • 16.1. Indonesia Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Radiopharmaceuticals Market

  • 17.1. South Korea Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Radiopharmaceuticals Market

  • 18.1. Taiwan Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Radiopharmaceuticals Market

  • 19.1. South East Asia Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Radiopharmaceuticals Market

  • 20.1. Western Europe Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Radiopharmaceuticals Market

  • 21.1. UK Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Radiopharmaceuticals Market

  • 22.1. Germany Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Radiopharmaceuticals Market

  • 23.1. France Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Radiopharmaceuticals Market

  • 24.1. Italy Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Radiopharmaceuticals Market

  • 25.1. Spain Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Radiopharmaceuticals Market

  • 26.1. Eastern Europe Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Radiopharmaceuticals Market

  • 27.1. Russia Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Radiopharmaceuticals Market

  • 28.1. North America Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Radiopharmaceuticals Market

  • 29.1. USA Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Radiopharmaceuticals Market

  • 30.1. Canada Radiopharmaceuticals Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Radiopharmaceuticals Market

  • 31.1. South America Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Radiopharmaceuticals Market

  • 32.1. Brazil Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Radiopharmaceuticals Market

  • 33.1. Middle East Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Radiopharmaceuticals Market

  • 34.1. Africa Radiopharmaceuticals Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Radiopharmaceuticals Market, Segmentation By Type, Segmentation By Application, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Radiopharmaceuticals Market Regulatory and Investment Landscape

36. Radiopharmaceuticals Market Competitive Landscape And Company Profiles

  • 36.1. Radiopharmaceuticals Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Radiopharmaceuticals Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Radiopharmaceuticals Market Company Profiles
    • 36.3.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Curium Pharma Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. General Electric Company (GE) Overview, Products and Services, Strategy and Financial Analysis

37. Radiopharmaceuticals Market Other Major And Innovative Companies

  • IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope

38. Global Radiopharmaceuticals Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Radiopharmaceuticals Market

40. Radiopharmaceuticals Market High Potential Countries, Segments and Strategies

  • 40.1 Radiopharmaceuticals Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Radiopharmaceuticals Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Radiopharmaceuticals Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer